We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.72% | 14.25 | 14.00 | 14.50 | 14.25 | 14.00 | 14.00 | 1,152,228 | 11:56:50 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -11.05 | 134.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/6/2024 12:23 | Connello, A stock price is controlled by traders, not investors. Investors have already acted. Traders are not interested in videos or potential. Many are not even aware of what the company actually do or make. Traders are only interested in trying to profit or mitigate loss. That's it. They buy and sell according to what the 'herd' are doing. It's irrational and emotional fear and greed. But this behaviour is patterned and therefore 'predictable'. The mistake most PI's make is thinking like yourself. | 2tyke | |
14/6/2024 10:02 | Sci You don’t get it and simply don’t understand reporting requirements. Your post went on about last update was Nov and this below. Also the CEO hinted about multiple complete responses when in fact data from additional patients would have to be RNSd NO They have reiterated details of the 85% including March this year in an RNS. IF it was not on track as previously reported obligations would start to kick in. Regarding stating they must RNS new data, no not correct. They have said 70% target, current 85% response rate, 90% chance of hitting 70%. If that hasn’t changed they don’t need to say, still on target, via regulatory news. They have released a number of news items as regulatory which have not been price sensitive but they continue to release them as such. The nomad decides what is and isn’t sensitive, not random CFD chasing private investors. It seems to me they are simply holding out for the 70% target to be exceeded, then I wonder if they will cease to continue scib1 Last report 30 in scib, if 85% or more is the norm then 27 is achievable just from those . One was heading to 30% shrinkage, which would make 12 out of 13 if they did (92%) | chilltime | |
14/6/2024 09:24 | Sci102 Member since: 01 Dec 2023 Only posts on Scancell Enough said? | dominiccummings | |
14/6/2024 09:16 | OK enough is enough. It is nearly time for my exit so I'm gonna let you fools resume the pumping. Goodbye | sci102 | |
14/6/2024 08:47 | at least some trades this morning. Struggling to understand the low volumes here particularly after the Lindy interview..... | connello | |
14/6/2024 08:37 | the registrational trial is no different to the trial we are currently running from a patient perspective, a control arm does not add complexity only costs but what makes Scancell so interesting is the number of patients YOU do not need 1000's to prove 85% ORR because its non toxic ... it makes interim approval very easy WeTookPelham Posts: 3,960 Price: 11.00 No Opinion RE: A pivitol week, a pivtol video...Today 08:00 @mattrempit - fair enough. But my issue is you saying Lindy "wants" Scancell to take this through to the end, (with the inevitable costs and time). I don't think this is realistic, more importantly I don't think Lindy believes this is realistic either (IMO), and she categorically says they would consider offers from big pharma. Hence I felt I had to respond to your comment. | inanaco | |
14/6/2024 08:28 | SC102 concentrating on patient numbers is pointless has no value Scancell release data at specific points on the current trials ... the Null hypothesis THAT DATA IS THEN BANKED ............ the software i have found proves Scancell data is correct you seem to be obsessed with numbers ... but have no shares ! | inanaco | |
14/6/2024 08:16 | Nothing is ever your fault Sci. A narcissist could never accept that. | countbruga | |
14/6/2024 08:00 | The problem those folks have of attacking me is plain and simple just one post done years ago which one has failed Scib1 or Keytruda = no risk ...... they have to work together | inanaco | |
14/6/2024 07:57 | tf he is after me ... he told us all his job was probabilities and he produced a page of A4 drivel .. nobody averages cancer shrinkage as an endpoint !! or eliminates the failures to make the maths work so i can see why Ruck would be "embarrassed" his efforts are on par with SC102 | inanaco | |
14/6/2024 07:55 | TF, Maybe I should have said narcissists (plural):) | ruckrover | |
14/6/2024 07:53 | Inan,"Buy and Hold"Whilst I disagree with the strategy in general I have bought and I am holding! | ruckrover | |
14/6/2024 07:52 | Well said Ruck, (but in your last para you are very hard on Lozan). | torquayfan | |
14/6/2024 07:51 | Ruckrover except I have your Towel ............. and i can see your 40p retirement !! coming soon SC102 cannot do that ! | inanaco | |
14/6/2024 07:49 | Fact SC102 No Shares and probably no money as Money talks ... loudest Redmile Vulpes Vulpes sit on the board and both would be aware of Scancells desire to run to approval no sells we are looking at a very serious share price if we have an approved product with a 16 year patent with sales of $1.5b which could double again if we target adjuvant melanoma Scancell could get approval at the start of phase 3 if the ORR is above 70% I have shown many trials with this happening ..... If you have followed my posts you will make a fortune Buy and Hold | inanaco | |
14/6/2024 07:41 | Chilltime thanks for those posts. I see the 'Litter Free' thread has been cancelled, (with the result that Sci102 is here now). But Sci102 is best on filter IMO. | torquayfan | |
14/6/2024 07:35 | "Fact" 😅😅 | sci102 | |
14/6/2024 07:34 | Sci102 filtered. | rogerbridge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions